Form 4: Tandem Diabetes CSO Gasser Reports RSU Vesting & Tax Withholding

Tandem Diabetes Care's EVP, Chief Strategy Officer, Elizabeth Gasser, reported scheduled vesting of Restricted Stock Units and associated tax withholdings.

Summary

• Elizabeth Anne Gasser, EVP, Chief Strategy Officer of Tandem Diabetes Care Inc. (TNDM), reported changes in beneficial ownership.
• On February 17, 2026, Gasser acquired 1,503 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• Concurrently, 887 shares were disposed of at $18.95 per share to satisfy tax withholding requirements related to the RSU vesting.
• On the same date, Gasser acquired an additional 1,097 shares of common stock from RSU vesting.
• Another 647 shares were disposed of at $18.95 per share for tax withholding purposes.
• Following these transactions, Gasser directly beneficially owns 1,066 shares of common stock.
• Gasser also indirectly beneficially owns 25,949 shares through The Gasser Family Trust dated September 1, 2011.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting routine executive compensation and retention through RSU vesting, with no discretionary sales by the insider, indicating continued alignment with company performance.

Positives

• Continued vesting of Restricted Stock Units indicates ongoing compensation and retention of a key executive.
• The transactions are part of a pre-arranged 10b5-1 plan, suggesting orderly and planned equity management.
• The insider is not selling shares for personal liquidity but rather to cover tax obligations, indicating continued alignment with shareholder interests.

Negatives

• A total of 1,534 shares (887 + 647) were disposed of to cover tax liabilities, reducing the direct beneficial ownership of the executive.

Future Outlook

The filing details future scheduled transactions related to executive compensation, specifically the vesting of Restricted Stock Units on February 17, 2026. These transactions are part of pre-existing long-term incentive plans with defined vesting schedules extending beyond this date.

Management Comments

• Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Industry Context

StockSavvy.ai notes that routine Form 4 filings detailing RSU vesting and tax withholding are common across industries, particularly for growth-oriented technology and medical device companies like Tandem Diabetes Care. These filings reflect standard executive compensation practices designed to align management incentives with long-term shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a significant component of executive compensation is a common practice among publicly traded companies, particularly in the biotechnology and medical device sectors, similar to companies like Dexcom (DXCM) or Insulet Corporation (PODD).
• The practice of withholding shares to cover tax obligations upon RSU vesting is standard and aligns with typical equity compensation administration across global benchmarks.
• The disclosure of these transactions under a Rule 10b5-1 plan is also a standard corporate governance practice, demonstrating a commitment to transparency and mitigating concerns about opportunistic insider trading.

Stakeholder Impact

• Shareholders: The vesting of RSUs and subsequent tax withholding is a standard part of executive compensation, aligning executive incentives with long-term shareholder value. No direct impact on share price from these routine, pre-scheduled transactions.
• Employees: Reflects the company's ongoing use of equity-based compensation plans to attract and retain key talent.

Next Steps

• Remaining shares from the May 25, 2023 RSU award will vest in eight equal quarterly installments after May 15, 2024.
• Remaining shares from the May 23, 2024 RSU award will vest in eight equal quarterly installments after May 15, 2025.

Key Dates

Recommendation

This Form 4 filing details routine, pre-scheduled executive compensation events (RSU vesting and tax withholding) under a 10b5-1 plan. It does not indicate any discretionary buying or selling by the insider for personal gain, nor does it contain new information about the company's operational or financial performance. Therefore, it provides no new fundamental basis for a change in investment recommendation, suggesting a 'hold' position for existing investors.

Keywords

Tandem Diabetes Care, TNDM, Elizabeth Gasser, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Tax Withholding, Executive Compensation, 10b5-1 Plan, Beneficial Ownership